SMYD3 and cancer: Our results imply that SMYD3‐mediated methylation of HER2 at Lysine 175 may regulate the formation of HER2 homodimer and subsequent autophosphorylation and suggest that the SMYD3‐mediated methylation pathway seems to be a good target for development of novel anti‐cancer therapy.